每经AI快讯，北大医药（SZ 000788，收盘价：6.18元）10月10日晚间发布关于持股5%以上股东部分股 份解除质押的公告。公告称，公司于近日收到持股5%以上股东北大医疗管理有限责任公司（以下简 称"北大医疗"）提供的《中国证券登记结算有限责任公司解除证券质押登记通知》，获悉北大医疗持有 的公司部分股份办理了解除质押手续。 每经头条（nbdtoutiao）——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后，这些城市怎么 样了？ （记者 曾健辉） 2025年1至6月份，北大医药的营业收入构成为：药品流通业占比65.53%，药品制造占比34.47%。 截至发稿，北大医药市值为37亿元。 截至本公告日，北大医疗累计质押股数约为3462万股，占其所持股份比例为49.22%。 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-076 北大医药股份有限公司 关于获得《药品补充申请批准通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北大医药股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的《药品补充申请批准通知书》。现将相关情况公告如下： 一、药品基本情况 1、药品通用名称：奥氮平片 注册分类：化学药品 药品批准文号：国药准字H20258218 上市许可持有人：北大医药股份有限公司 药品生产企业：北大医药股份有限公司 审批主要结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品此次申请事项符合药品注册的有关要求，批准本品如下补充申请事项:增加 5mg规格，核发药品批准文号。 二、药品的其他相关情况 奥氮平是一种抗精神病药，用于治疗精神分裂症；对奥氮平初次治疗有效的 患者，巩固治疗可以有效维持临床症状改善；奥氮平也用于治疗中、重度躁狂发 作；对奥氮平治疗有效的躁狂发作患者，奥氮平可以预防双相情感障碍的复发。 三、对公司的影响 公司本产品的获批，进一步完善了公司在精神类疾病领域 ...

南财智讯10月10日电，北大医药公告，持股5%以上股东北大医疗管理有限责任公司持有的公司3461.54 万股股份于2025年9月30日解除质押，占其所持股份的49.22%，占公司总股本的5.81%。截至公告披露 日，北大医疗及其一致行动人累计被质押股份3461.54万股，占其所持股份的49.22%，占公司总股本的 5.81%。 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-077 北大医药股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于近日收到持股5%以上股东北大 医疗管理有限责任公司（以下简称"北大医疗"）提供的《中国证券登记结算有限 责任公司解除证券质押登记通知》，获悉北大医疗持有的公司部分股份办理了解除 质押手续。现将相关情况公告如下： 一、股东所持公司部分股份解除质押基本情况 | 股东名称 | 是否为控股 股东或第一 大股东及其 一致行动人 | | 本次解除质押 股份数量（股） | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 北大医疗管理有限 责任公司 | | 否 | 34,615,385 | 49.22% | 5.81% | 2024-03-28 | 2025-09-30 | 中国农业银 行股份有限 ...

Group 1: Drug Approval Announcement - North China Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Apremilast Tablets, a PDE4 inhibitor, approved by the National Medical Products Administration [1][2][4] - The drug is indicated for the treatment of moderate to severe plaque psoriasis in adults and is recognized as a first-line systemic treatment in the 2023 Chinese Psoriasis Treatment Guidelines [4] Group 2: Impact on the Company - The approval of Apremilast Tablets enhances the company's product portfolio and competitiveness in the immunomodulator market, positively influencing future performance [4] Group 3: Dividend Distribution Announcement - The company has approved a cash dividend of 0.30 RMB per 10 shares, totaling approximately 17.88 million RMB, based on a total share capital of 595,987,425 shares [5][9] - The dividend distribution will occur on October 13, 2025, with the record date set for October 10, 2025 [10][11]

Core Points - Peking University Medicine announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.30 yuan (including tax) for every 10 shares based on a total share capital of 595,987,425 shares [2] Group 1 - The record date for the dividend is set for October 10, 2025 [2] - The ex-dividend date is scheduled for October 13, 2025 [2]

Core Viewpoint - Recently, the company received the Drug Registration Certificate approved by the National Medical Products Administration [2] Group 1 - The company announced the receipt of the Drug Registration Certificate on the evening of September 25 [2]

证券代码：000788 证券简称：北大医药 公告编号：2025-075 北大医药股份有限公司 2025年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东会审议通过利润分配方案等情况 1.公司2025年第三次临时股东会审议通过的2025年半年度利润分配方案为： 以现有总股本 595,987,425 股为基数,以可供股东分配的利润向公司全体股东每 10 股派发现金 0.30 元（含税），总计派发红利 17,879,622.75 元（含税。计算 公式为：总股本 595,987,425 股÷10 股×0.30 元），本次利润分配不送红股， 不以资本公积金转增股本。 2.若在分配预案实施前公司总股本由于可转债、股份回购、股权激励、再融 资新增股份上市等原因发生变化的，将按照分配总额不变的原则对分配比例进行 调整。自分配预案披露至实施期间公司股本总额未发生变化。 3.本次实施的分配方案与股东会审议通过的分配方案一致。 4.本次实施分配方案距离股东会审议通过的时间未超过两个月。 二、本次实施的权益分派方案 本公司2025年半年度权益分派方案为 ...

Core Viewpoint - Beida Pharmaceutical (000788.SZ) has received the Drug Registration Certificate from the National Medical Products Administration for Apremilast tablets, indicating a significant advancement in its product pipeline for treating moderate to severe plaque psoriasis in adults [1] Group 1: Product Information - Apremilast is a small molecule inhibitor specifically targeting phosphodiesterase-4 (PDE4), which regulates intracellular inflammatory signaling pathways [1] - The drug effectively inhibits the release of pro-inflammatory factors and increases the production of anti-inflammatory factors, allowing for precise control of inflammatory responses [1] - Apremilast tablets are recognized for their rapid onset of action, clear efficacy, and high safety profile, making them a first-line systemic treatment option as per the "Chinese Psoriasis Diagnosis and Treatment Guidelines (2023 Edition)" [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for the drug Apremilast tablets, which are intended for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] Company Summary - The approval of Apremilast tablets marks a significant milestone for the company, expanding its product portfolio in the dermatology sector [1] - This drug is specifically aimed at treating adult patients with moderate to severe plaque psoriasis, indicating a targeted approach to addressing this skin condition [1] Industry Summary - The approval aligns with the growing demand for effective treatments for psoriasis, a chronic skin condition affecting a substantial portion of the population [1] - The introduction of Apremilast tablets may enhance competition within the dermatology market, particularly among companies offering psoriasis treatments [1]